- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03052257
Improve Glaucoma Medication Adherence (MAGIC)
Improving Glaucoma Medication Adherence
Study Overview
Status
Conditions
Detailed Description
The purpose if this study is to improve glaucoma medication adherence in Veterans with medically-treated glaucoma. The study design is a single-site randomized controlled trial. Specific Aim 1. Evaluate the impact of an intervention to improve glaucoma medication adherence among Veterans at 6-month follow up.
Hypothesis 1: Veterans randomized to the intervention will have a greater proportion of prescribed glaucoma medication doses taken as measured by the electronic medication monitor in the 6 months following the intervention compared to Veterans randomized to the control arm.
The primary outcome for hypothesis 1A is the proportion of prescribed doses taken according to the electronic monitor. Participants in both arms will receive the electronic monitor or "smart bottle," which wirelessly transmits the date and time of opening of the smart bottle to the study team. From these medication events, the proportion of prescribed doses will be derived, defined as the ratio of the number of times the smart bottle was opened to the required number of doses prescribed according to the medical record over the period of time that the bottle is in use. For example, if a participant is advised to take his or her glaucoma drop twice a day for the 180 days that the bottle is in use and the smart bottle reveals 135 openings over the same time period, the proportion of prescribed doses taken is 37.5%.
Specific Aim 2. Evaluate the impact of the intervention on intensification of glaucoma therapy among Veterans at 12-month follow-up.
Hypothesis 2: The proportion of Veterans in the intervention arm that are prescribed more intensive glaucoma therapy, defined as addition of adjuvant glaucoma medication or recommendation for laser or glaucoma surgery will be less than the proportion of Veterans in the control arm who are prescribed more intensive glaucoma therapy in the 12 months following the intervention.
Baseline data collection will include cataloging the current glaucoma medication regimen prescribed to the participant. Chart abstractions will be performed at 12 months following the baseline visit and intensification of glaucoma therapy will be defined as either 1) the addition of another glaucoma medication to the baseline regimen, 2) recommendation for glaucoma laser treatment, or 3) recommendation for glaucoma surgery in the 12 months following the baseline visit . The investigators will collect these data at 12 months because the Metrics study suggested that 55% of participants in the control arm will have intensification of therapy within one year.
Specific Aim 3. Evaluate the incremental cost-effectiveness and budget and workflow impacts of the intervention compared to usual care.
Hypothesis 3: The intervention will be cost-effectiveness for the following ratios: 1) cost per percentage improvement in medication adherence; 2) cost per blindness averted; and 3) cost per quality-adjusted-life years saved.
A direct measurement approach will be used to estimate per-patient intervention and control arm costs. Glaucoma-related health care utilization costs will be derived from VA administrative datasets. The cost estimates will be combined with observed improvement in medication adherence and reduction in escalation in therapy to estimate the first two incremental cost effectiveness ratios. Simulation using Markov modeling will be used to estimate the incremental cost per blindness averted and quality-adjusted life years (QALYs) gained. Cost estimates and labor time data collected will be combined with glaucoma prevalence rates among Veterans to estimate overall budget and workload impacts to the VA healthcare system.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Durham VA Medical Center, Durham, NC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of open angle glaucoma [primary open angle glaucoma, pigment dispersion glaucoma, pseudoexfoliation glaucoma, combined mechanism glaucoma, low tension glaucoma] recorded in the medical record
- Prescribed glaucoma eye drops,
Visual field performed within the last 9 months.
- As visual field testing is standard care glaucoma and the investigators wish to establish baseline glaucoma severity, the investigators will require that subjects have a visual field test documented in the chart within 9 months of enrollment.
Exclusion Criteria:
Exclusion criteria for patients At Screener:
"How confident are you that you always remember to use your glaucoma medications?"
- not at all confident
- somewhat confident
- very confident)
And "In the past 4 weeks, did you ever forget to take your medicine?"
- Veterans who respond both "very confident" and "no", respectively, will be excluded
Inclusion criteria for companions at screener:
- Willing to participate in assisting the patient with glaucoma drops and
- Willing to accompany the patient to the intervention visit for participants in the intervention arm or eye health education visit for participants in the control arm.
Exclusion criteria for companions: Unable or unwilling to attend baseline visit and intervention or control arm educational session with patient participant.
Exclusion criteria for patients or companions:
- Lacks proficiency in English,
- Lacks either a cell phone or landline phone.
Exclusion criteria for patients post randomization:
- Decision by patient and provider to cease glaucoma medication use
- Change in functional status such that the drops are no longer administered by the patient or the companion (such as nursing home care)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm).
All participants will be provided with a "smart bottle" to house one of their glaucoma medications.
The smart bottle records the date and time that the bottle is opened.
|
Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation.
An individualized schedule for dosing of glaucoma medications.
Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
Participants will be provided with a "smart bottle" to house one of their glaucoma medications.
The smart bottle records the date and time that the bottle is opened.
For participants in the intervention arm only, a reminder through AdhereTech will be activated.
Other Names:
|
Active Comparator: Control
Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm).
All participants will be provided with a "smart bottle" to house one of their glaucoma medications.
The smart bottle records the date and time that the bottle is opened.
|
The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
Participants will be provided with a "smart bottle" to house one of their glaucoma medications.
The smart bottle records the date and time that the bottle is opened.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Prescribed Glaucoma Medication Doses Taken on Schedule
Time Frame: Randomization to 6 Months
|
Will veterans randomized to the intervention have a greater proportion of prescribed glaucoma medication doses taken as measured by the electronic medication monitor in the 6 months following the intervention compared to Veterans randomized to the control arm?
The electronic bottle records the date and time that the bottle is opened.
For participants in the intervention arm only, a reminder through the electronic bottle will be activated.
The outcome measure is the proportion of prescribed doses taken with a minimum of Zero and a maximum of One; where higher scores indicate more adherence.
|
Randomization to 6 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Newly Prescribed Glaucoma Therapy
Time Frame: 12 Months
|
Will the proportion of Veterans in the intervention arm that are prescribed more intensive glaucoma therapy be less than the proportion of Veterans in the control arm who are prescribed more intensive glaucoma therapy in the 12 months following the intervention?
Baseline data collection will include cataloging the current glaucoma medication regimen prescribed to the participant.
Chart abstractions will be performed at 12 months following the baseline visit and intensification of glaucoma therapy will be defined as either 1) the addition of another glaucoma medication to the baseline regimen, 2) recommendation for glaucoma laser treatment, or 3) recommendation for glaucoma surgery in the 12 months following the baseline visit .
|
12 Months
|
Cost-effectiveness Compared to Usual Care for Cost Per Percentage Improvement in Medication Adherence
Time Frame: 12 months
|
Will the intervention be cost-effectiveness compared to usual care for cost per percentage improvement in medication adherence
|
12 months
|
VA Budget Impacts
Time Frame: 12 months
|
The investigators will investigate the overall budget impacts to the VA healthcare system.
|
12 months
|
VA Healthcare Workflow Effectiveness
Time Frame: 12 months
|
The investigators will investigate the overall workload impacts to the VA healthcare system.
Cost estimates and labor time data collected will be combined with glaucoma prevalence rates among Veterans to estimate overall workload impacts to the VA healthcare system.
|
12 months
|
Cost-effectiveness Compared to Usual Care for Cost Per Blindness Averted
Time Frame: 12 months
|
Will the intervention be cost-effectiveness compared to usual care for cost per blindness averted
|
12 months
|
Cost-effectiveness Compared to Usual Care for Cost Per Quality-adjusted-life Years Saved.
Time Frame: 12 months
|
Will the intervention be cost-effectiveness compared to usual care for cost per quality-adjusted-life years saved?
|
12 months
|
VA Workflow Effectiveness
Time Frame: 12 months
|
The investigators will investigate the overall workload impacts to the VA healthcare system.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kelly W. Muir, MD MHSc, Durham VA Medical Center, Durham, NC
Publications and helpful links
General Publications
- Hein AM, Rosdahl JA, Bosworth HB, Woolson SL, Olsen MK, Kirshner MA, Muir KW. The Association of an Upper Extremity Functional Survey and Glaucoma Medication Administration Success. Curr Eye Res. 2019 Oct;44(10):1150-1156. doi: 10.1080/02713683.2019.1625405. Epub 2019 Jun 11.
- Muir KW, Rosdahl JA, Hein AM, Woolson S, Olsen MK, Kirshner M, Sexton M, Bosworth HB. Improved Glaucoma Medication Adherence in a Randomized Controlled Trial. Ophthalmol Glaucoma. 2022 Jan-Feb;5(1):40-46. doi: 10.1016/j.ogla.2021.04.006. Epub 2021 Apr 20.
- Rosdahl JA, Hein AM, Bosworth HB, Woolson S, Olsen M, Kirshner M, Hung A, Muir KW. Randomized controlled trial of an education-based intervention to improve medication adherence: Design considerations in the medication adherence in glaucoma to improve care study. Clin Trials. 2021 Jun;18(3):343-350. doi: 10.1177/1740774520988291. Epub 2021 Jan 25.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIR 15-113
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama
Clinical Trials on Educational - glaucoma
-
Maisonneuve-Rosemont HospitalPfizerCompletedGlaucoma Medication AdherenceCanada
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineUnknown
-
Federal University of São PauloUnknown
-
Ain Shams UniversityCompletedGlaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Secondary
-
Myra Vision Inc.Recruiting
-
University of MichiganNational Institute on Minority Health and Health Disparities (NIMHD)Not yet recruiting
-
Centro Hospitalar Universitário Lisboa NorteUnidade Local de Saúde do Alto Minho; ACES Lisboa Norte; Equipa Regional dos... and other collaboratorsEnrolling by invitation
-
Dietrich-Bonhoeffer-KlinikumCompleted
-
Al Watany Eye HospitalMoorfields Eye Hospital Centre Abu DhabiRecruiting
-
Odense University HospitalTerminated